GlobeNewswire Inc | Sep 22, 2021 07:30AM EDT

September 22, 2021

NESS ZIONA, Israel, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will participate in the Cantor Global Healthcare Conference, taking place virtually from September 27th 30th, 2021.

Cantor Global Healthcare Conference Presentation Information:Format Fireside chat discussion and 1-on-1 meetingsSpeaker: Dr. Alon Seri-Levy, Chief Executive Officer and Mr. Gilad Mamlok, Chief Financial OfficerDate: Thursday, September 30^thTime: Discussion available on demand beginning Thursday, September 30^th 10:40 a.m. ET (TRACK 3)To To listen to the discussion, click here. A replay will be archived forListen 30 days at this link (or go to www.sol-gel.com to access within the Investors/Events and Presentations section).

About Sol-Gel Technologies

Sol-Gelis a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for TWYNEO, which is FDA approved for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older; and EPSOLAY, under investigation for the treatment of inflammatory lesions of rosacea with an NDA filed with the FDA and a PDUFA goal date that was set forApril26,2021. Action on the NDA for EPSOLAY has not yet been taken due to the inability of the FDA to conduct a pre-approval inspection of the production site of EPSOLAY as a result of COVID-19 travel restrictions. Both product candidates are exclusively licensed forU.S.commercialization withGalderma.

The Companys pipeline also includes early-stage topical drug candidates SGT-210 (erlotinib gel) under investigation for the treatment ofpalmoplantar keratoderma, SGT-310 (tapinarof cream, 1%) and SGT-510 (roflumilast) under investigation for the treatment ofplaque psoriasis and other dermatologic indications.

For additional information, please visitwww.sol-gel.com.

Contact:

Irina KofflerInvestor relations,LifeSci Advisorsikoffler@lifesciadvisors.com+1-917-734-7387

Sol-Gel TechnologiesGilad MamlokChief Financial Officergilad.mamlok@sol-gel.com